Literature DB >> 7552994

Defective B cell development and function in Btk-deficient mice.

W N Khan1, F W Alt, R M Gerstein, B A Malynn, I Larsson, G Rathbun, L Davidson, S Müller, A B Kantor, L A Herzenberg.   

Abstract

Mutations in the Bruton's tyrosine kinase (Btk) gene have been linked to severe early B cell developmental blocks in human X-linked agammaglobulinemia (XLA), and to milder B cell activation deficiencies in murine X-linked immune deficiency (Xid). To elucidate unequivocally potential Btk functions in mice, we generated mutations in embryonic stem cells, which eliminated the ability to encode Btk pleckstrin homology or kinase domains, and assayed their effects by RAG2-deficient blastocyst complementation or introduction into the germline. Both mutations block expression of Btk protein and lead to reduced numbers of mature conventional B cells, severe B1 cell deficiency, serum IgM and IgG3 deficiency, and defective responses in vitro to various B cell activators and in vivo to immunization with thymus-independent type II antigens. These results prove that lack of Btk function results in an Xid phenotype and further suggest a differential requirement for Btk during the early stages of murine versus human B lymphocyte development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7552994     DOI: 10.1016/1074-7613(95)90114-0

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  218 in total

Review 1.  Early B cell defects.

Authors:  H B Gaspar; M E Conley
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.

Authors:  S Nisitani; A B Satterthwaite; K Akashi; I L Weissman; O N Witte; M I Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals.

Authors:  F Loder; B Mutschler; R J Ray; C J Paige; P Sideras; R Torres; M C Lamers; R Carsetti
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

Review 4.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

5.  X-chromosome-linked immune-deficient mice have B-1b cells.

Authors:  J Riggs; K Howell; B Matechin; R Matlack; A Pennello; R Chiasson
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

6.  BLNK: molecular scaffolding through 'cis'-mediated organization of signaling proteins.

Authors:  Christopher W Chiu; Mark Dalton; Masamichi Ishiai; Tomohiro Kurosaki; Andrew C Chan
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

7.  Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI.

Authors:  Jiro Kitaura; Jinming Song; Mindy Tsai; Koichi Asai; Mari Maeda-Yamamoto; Attila Mocsai; Yuko Kawakami; Fu-Tong Liu; Clifford A Lowell; B George Barisas; Stephen J Galli; Toshiaki Kawakami
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

8.  Impaired B cell development and function in mice with a targeted disruption of the homeobox gene Hex.

Authors:  Clifford W Bogue; Ping-Xia Zhang; James McGrath; Harris C Jacobs; Ramsay L Fuleihan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-08       Impact factor: 11.205

9.  Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex.

Authors:  Shiann-Tarng Jou; Nick Carpino; Yutaka Takahashi; Roland Piekorz; Jyh-Rong Chao; Neena Carpino; Demin Wang; James N Ihle
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

10.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.